Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 4
1998 8
1999 1
2000 7
2001 5
2002 11
2003 11
2004 7
2005 15
2006 14
2007 18
2008 19
2009 13
2010 16
2011 15
2012 19
2013 20
2014 25
2015 22
2016 17
2017 27
2018 21
2019 30
2020 28
2021 22
2022 33
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-drug conjugates: in search of partners of choice.
Fuentes-Antrás J, Genta S, Vijenthira A, Siu LL. Fuentes-Antrás J, et al. Among authors: siu ll. Trends Cancer. 2023 Apr;9(4):339-354. doi: 10.1016/j.trecan.2023.01.003. Epub 2023 Feb 4. Trends Cancer. 2023. PMID: 36746689 Free article. Review.
Molecular profiling for precision cancer therapies.
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Malone ER, et al. Among authors: siu ll. Genome Med. 2020 Jan 14;12(1):8. doi: 10.1186/s13073-019-0703-1. Genome Med. 2020. PMID: 31937368 Free PMC article. Review.
Circulating tumor DNA and liquid biopsy in oncology.
Cescon DW, Bratman SV, Chan SM, Siu LL. Cescon DW, et al. Among authors: siu ll. Nat Cancer. 2020 Mar;1(3):276-290. doi: 10.1038/s43018-020-0043-5. Epub 2020 Mar 20. Nat Cancer. 2020. PMID: 35122035 Review.
Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C, Lee JJ, Siu LL. Le Tourneau C, et al. Among authors: siu ll. J Natl Cancer Inst. 2009 May 20;101(10):708-20. doi: 10.1093/jnci/djp079. Epub 2009 May 12. J Natl Cancer Inst. 2009. PMID: 19436029 Free PMC article. Review.
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.
Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, Ho GF, Caguioa PB, Ngamphaiboon N, Ho C, Aziz MASA, Ng QS, Yen CJ, Soparattanapaisarn N, Ngan RK, Kho SK, Tiambeng MLA, Yun T, Sriuranpong V, Algazi AP, Cheng A, Massarelli E, Swaby RF, Saraf S, Yuan J, Siu LL. Chan ATC, et al. Among authors: siu ll. Ann Oncol. 2023 Mar;34(3):251-261. doi: 10.1016/j.annonc.2022.12.007. Epub 2022 Dec 16. Ann Oncol. 2023. PMID: 36535566 Free article. Clinical Trial.
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ. Bratman SV, et al. Among authors: siu ll. Nat Cancer. 2020 Sep;1(9):873-881. doi: 10.1038/s43018-020-0096-5. Epub 2020 Aug 3. Nat Cancer. 2020. PMID: 35121950
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C. Siu LL, et al. Clin Cancer Res. 2022 Jan 1;28(1):57-70. doi: 10.1158/1078-0432.CCR-21-2160. Epub 2021 Oct 1. Clin Cancer Res. 2022. PMID: 34598945 Free PMC article.
420 results